Natco Pharma
BSE 524816
9 stories, newest first.
- Allotment of ~1.71 crore equity shares at ₹750 each under rights issue
- Rights Issue period closes today; issue of up to Rs.12,794 millions approved at Rs.750 per share
- Carboplatin Injection, generic of Paraplatin, launched in the U.S. market
- Natco Pharma in focus after Abu Dhabi Investment Authority acquired 1.73 lakh shares
- Promoter creates pledge of 8,50,000 equity shares, 0.47% of total share capital
- Investment in eGenesis raised to US$16.70 million via convertible promissory notes
- Record Date Fixed for Rights Issue of Equity Shares
- Board approves Rights Issue of up to ₹12,79,35,61,500 at ₹750 per share, ratio 2:21
- Board Approves Rights Issue of ₹1,279.35 Crore at ₹750 Per Share, Ratio 2:21
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.